DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,054 filers reported holding DANAHER CORPORATION in Q4 2021. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $897,334 | -3.3% | 3,560 | +1.8% | 0.31% | -3.4% |
Q4 2022 | $928,199 | +4.5% | 3,497 | +1.7% | 0.32% | -13.6% |
Q3 2022 | $888,000 | +4.1% | 3,437 | +2.2% | 0.38% | -6.2% |
Q2 2022 | $853,000 | -2.5% | 3,364 | +12.7% | 0.40% | +19.0% |
Q1 2022 | $875,000 | -9.0% | 2,984 | +2.1% | 0.34% | +0.6% |
Q4 2021 | $962,000 | +7.5% | 2,923 | -0.5% | 0.33% | +3.1% |
Q3 2021 | $895,000 | +21.1% | 2,938 | +6.7% | 0.32% | +21.8% |
Q2 2021 | $739,000 | -2.1% | 2,753 | -17.9% | 0.27% | -13.1% |
Q1 2021 | $755,000 | +9.6% | 3,353 | +8.1% | 0.31% | +3.0% |
Q4 2020 | $689,000 | +13.9% | 3,101 | +10.4% | 0.30% | +3.5% |
Q3 2020 | $605,000 | +35.7% | 2,810 | +11.5% | 0.29% | +26.4% |
Q2 2020 | $446,000 | +59.9% | 2,520 | +25.2% | 0.23% | +36.7% |
Q1 2020 | $279,000 | -5.1% | 2,013 | +5.2% | 0.17% | +27.7% |
Q4 2019 | $294,000 | +6.5% | 1,913 | 0.0% | 0.13% | +8.3% |
Q3 2019 | $276,000 | +1.1% | 1,913 | 0.0% | 0.12% | -2.4% |
Q2 2019 | $273,000 | +7.9% | 1,913 | 0.0% | 0.12% | +6.0% |
Q1 2019 | $253,000 | +21.6% | 1,913 | 0.0% | 0.12% | -1.7% |
Q3 2018 | $208,000 | – | 1,913 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |